India and Oman pharmaceutical industry manufactures a wide range of generic drugs and medicines to cater to the diverse needs of patients across multiple therapeutic areas. The industry also provides cost-effective drugs which are highly accessible to people in both the countries owing to increasing generics penetration.

India and Oman Pharmaceutical Industry Market is estimated to be valued at US$ 34 billion in 2024 and is expected to exhibit a CAGR of 9.3% over the forecast period 2024-2031, as highlighted in a new report published by Coherent Market Insights.

Market Opportunity:

The opportunity to meet rising healthcare expenditure in emerging economies presents a lucrative avenue for players in India and Oman pharmaceutical industry. Both India and Oman have seen rapid economic development over the past few decades which has increased disposable incomes and boosted healthcare spending. However, per capita healthcare expenditure remains relatively low in these countries compared to developed nations. This leaves significant headroom for growth as income and investment in healthcare infrastructure continue to increase. Local manufacturers are well-positioned to cater to this demand and expand access to affordable treatment options for a variety of ailments. By leveraging their low-cost production capabilities and expertise in generic drugs, industry players can gain a sizable share of the rising healthcare budgets in these emerging pharmaceutical markets.

Porter’s Analysis
Threat of new entrants: The pharmaceutical industry requires high capital investment in R&D for drug development which acts as a barrier for new companies. Regulatory compliances related to clinical trials and product approval further increases entry barriers.

Bargaining power of buyers: The bargaining power of buyers is moderate due to the presence of generic manufacturers. However, customers have less influence over branded products which have strong brand loyalty.

Bargaining power of suppliers: Large pharmaceutical companies have significant influence over API and raw material suppliers due to their large volume requirements and standards. Suppliers also face high switchig costs.

Threat of new substitutes: Threat from new substitutes is low as drugs developed for different therapeutic areas require long development cycles and regulatory approvals. however, herbal and alternative medicine pose competition.

Competitive rivalry: The industry has strong competition among existing players. Companies compete on basis of new drug launches, production quality, and expanding hospital and retail sales networks.

SWOT Analysis
Strength: Wide acceptance of allopathic treatment, large patient pool, growing healthcare spending. Emergence of CROs supporting clinical trials.
Weakness: High dependency on imports for APIs and formulations, price controls affect margins. Low awareness in rural areas.
Opportunity: Rising lifestyle diseases, growing geriatric population, scope for herbal drugs. Export potential to African and Asian markets.
Threats: Stringent regulations delay approvals. Patent cliff of major drugs, price erosion due to generics.

Key Takeaways
India And Oman Pharmaceutical Industry Market Demand is expected to witness high growth during the forecast period owing to rising income levels, spreading health awareness, and government initiatives to strengthen healthcare infrastructure in both countries.

Regionally, India dominates the market and holds the largest share currently. The country accounts for around 3% of the global pharmaceutical production by volume. Favourable regulations, skilled manpower and presence of leading facilities are driving India's leading position. However, Oman is poised to be the fastest growing market in the region backed by initiatives to develop local manufacturing capabilities and reduce import dependence for drugs and medical devices.

Key players operating in India and Oman pharmaceutical industry are Sun Pharmaceutical Industries, Cipla, Dr. Reddy's Laboratories, AstraZeneca and GlaxoSmithKline. The market is quite competitive with the top 5 companies accounting for over 40% share. Companies are focused on expanding product portfolios through collaborations and leveraging theirstrong distribution network across various regions. However,smaller domestic players also have a growing presence, intensifying the competitive landscape.

Get More Insights on this Topic- https://www.dailyprbulletin.com/india-and-oman-pharmaceutical-industry-market-growth-analysis/